Acumen Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABOS research report →
About the company
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
- CEO
- Daniel J. O'Connell
- IPO
- 2021
- Employees
- 61
- HQ
- Newton, VA, US
Price Chart
- Market Cap
- $165.97M
- P/E
- -1.47
- P/S
- 0.00
- P/B
- 1.98
- EV/EBITDA
- -1.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -123.07%
- ROIC
- -96.51%
- Revenue
- $0 · 0.00%
- Net Income
- $-121,335,000 · -18.57%
- EPS
- $-2.00 · -16.96%
- Op Income
- $-123,832,000
- FCF YoY
- -34.09%
- 52W High
- $3.60
- 52W Low
- $1.14
- 50D MA
- $2.43
- 200D MA
- $2.28
- Beta
- 0.35
- Avg Volume
- 458.53K
Get TickerSpark's AI analysis on ABOS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Porter Derrell | other | 6,460 |
| Jun 17, 26 | Porter Derrell | other | 13,040 |
| Jun 15, 26 | Porter Derrell | sell | 6,460 |
| Jun 17, 26 | Porter Derrell | sell | 13,040 |
| Jun 16, 26 | Porter Derrell | sell | 12,800 |
| Jun 15, 26 | Porter Derrell | other | 6,460 |
| Jun 17, 26 | Porter Derrell | other | 13,040 |
| Jun 9, 26 | Fountain Nathan B | sell | 6,400 |
| Jun 3, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 53,250 |
| Jun 3, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 35,500 |
Our ABOS coverage
Recent articles, reports, and earnings notes.
No research on ABOS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABOS report →Similar companies
Peers in the same neighborhood.